Skip to content
drillr.ai
Sign up

AMGN

Amgen Inc.

NASDAQ · Healthcare · Drug Manufacturers - General · US

$436.90
−1.63%
Ask drillr

  • Aug 31, 2026, 07:15 UTC

    Amgen announced on Monday that its cholesterol drug Repatha reduced the risk of death by 20% in a study of over 12,000 high-risk patients.

    Source:

  • Aug 27, 2026, 06:00 UTC

    Amgen and AstraZeneca announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE (tezepelumab-ekko) in patients with eosinophilic esophagitis, showing statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints through week 52.

    Source:

  • Aug 23, 2026, 08:00 UTC

    Beutel Goodman & Co Ltd. reduced its stake in Amgen Inc. by 19.8% during the second quarter of 2026, selling 128,742 shares, according to a Form 13F filing.

    Source:

  • Aug 21, 2026, 08:51 UTC

    Bank of New York Mellon Corp reduced its stake in Amgen Inc. by 2.6% during the quarter, selling 97,857 shares, according to a recent SEC filing.

    Source:

  • Aug 20, 2026, 08:43 UTC

    Aegis Wealth Management LLC acquired a new stake in Amgen Inc., purchasing 2,162 shares valued at approximately $783,000, as disclosed in a recent SEC filing.

    Source:

  • Aug 19, 2026, 19:38 UTC

    Biopharma stocks including AbbVie, Amgen, Eli Lilly, Johnson & Johnson, and Merck rallied on Wednesday, with Merck jumping 12.4%.

    Source:

  • Aug 11, 2026, 11:24 UTC

    Zoomex launched twelve new USDT-margined stock perpetual contracts for UnitedHealth Group, General Electric, JPMorgan Chase, Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Walmart, Coca-Cola, PepsiCo, Mastercard, PayPal Holdings, and Berkshire Hathaway Class B, offering 24/7 long and short trading with up to 25x leverage.

    Source:

  • Aug 11, 2026, 08:31 UTC

    BeiGene and Amgen's jointly developed drug Tarlatamab (AnTaid) officially entered clinical use in China, with prescriptions issued at 29 hospitals across 17 cities as of August 10, and supply started on August 7 covering 80 cities and over 200 medical institutions.

    Source:

  • Aug 4, 2026, 20:14 UTC

    Amgen announced it is ending early development of its phase 1 obesity treatment.

    Source:

  • Aug 4, 2026, 20:11 UTC

    Amgen reported its Q2 2026 results on August 4, 2026, with revenue up 9.5% year-over-year to $10 billion, operating income up 32.3% to $3.514 billion, and diluted EPS of $4.37.

    Source:

  • Jul 31, 2026, 20:12 UTC

    Amgen disclosed that some data, including proprietary data, patient protected health information, and other information, had been stolen.

    Source:

  • Jul 30, 2026, 20:01 UTC

    Amgen's Board of Directors declared a $2.52 per share dividend for the third quarter of 2026.

    Source:

  • Jul 30, 2026, 17:07 UTC

    Amgen announced that the CHMP of the European Medicines Agency adopted a positive opinion supporting a broader use of Repatha before a first heart attack or stroke.

    Source:

  • Jul 24, 2026, 13:45 UTC

    Amgen submitted new evidence to the FDA on July 23, 2026, to challenge the proposed withdrawal of its rare-disease drug Tavneos from the U.S. market.

    Source:

  • Jul 22, 2026, 16:30 UTC

    Amgen filed a lawsuit against the Colorado Prescription Drug Affordability Review Board challenging the price cap on Enbrel.

    Source:

  • Jul 21, 2026, 15:10 UTC

    Amgen reached a $74 million settlement of a shareholder lawsuit accusing it of hiding a $10.7 billion tax bill from the IRS.

    Source:

  • Jul 20, 2026, 13:30 UTC

    The Colorado Prescription Drug Affordability Review Board capped the price of Amgen's drug Enbrel at US$600 per weekly dose, effective January 1, 2027.

    Source:

  • Jul 2, 2026, 23:54 UTC

    Judge Daniel Domenico suspended Colorado's price cap on the prescription drug Enbrel, blocking it while a lawsuit by Amgen proceeds.

    Source:

  • Jun 29, 2026, 20:46 UTC

    The New England Journal of Medicine retracted an article on a pivotal clinical trial for Amgen's Tavneos drug after FDA findings of altered patient outcome data and unblinding of researchers.

    Source:

  • Jun 19, 2026, 08:07 UTC

    Amgen India appointed Anjali Rao as executive director of human resources.

    Source:

  • Jun 11, 2026, 23:28 UTC

    Amgen hired a research firm to independently review Tavneos data after the U.S. health regulator proposed to withdraw the drug from the market.

    Source:

  • Jun 3, 2026, 13:43 UTC

    The European Commission granted marketing authorization to Amgen's drug IMDYLLTRA for the treatment of advanced small cell lung cancer.

    Source: